Literature DB >> 3589702

Alfa-2b interferon in the treatment of Hodgkin's disease and non-Hodgkin's lymphoma.

R D Leavitt, V Ratanatharathorn, H Ozer, J E Ultmann, C Portlock, J W Myers, D Kisner, S Norred, R J Spiegel, E M Bonnem.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3589702

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  9 in total

1.  Malignant lymphomas in HIV-seropositive patients. Frequency, features, and prognosis. Report on 31 cases.

Authors:  D Schürmann; D Dienemann; G Jautzke; J Cervos-Navarro; A Langford; H Stein; H D Pohle; B Ruf
Journal:  Klin Wochenschr       Date:  1991-10-02

Review 2.  The role of interferon as maintenance therapy in malignant lymphoma.

Authors:  A Avilés
Journal:  Med Oncol       Date:  1997 Sep-Dec       Impact factor: 3.064

3.  Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA.

Authors:  G P Rajan; B Seifert; O Prümmer; H I Joller-Jemelka; G Burg; R Dummer
Journal:  Arch Dermatol Res       Date:  1996-08       Impact factor: 3.017

Review 4.  Interferon-alpha in malignant and viral diseases. A review.

Authors:  R T Dorr
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

Review 5.  The management of follicular lymphoma.

Authors:  A Z Rohatiner; T A Lister
Journal:  Drugs       Date:  1994       Impact factor: 9.546

6.  A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma.

Authors:  A Rohatiner; J Radford; D Deakin; H Earl; S B Love; O Price; A Wilson; T A Lister
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640

Review 7.  The role of interferons in the treatment of malignant neoplasms.

Authors:  J R Murren; A C Buzaid
Journal:  Yale J Biol Med       Date:  1989 May-Jun

8.  Neutralising antibodies in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b.

Authors:  J B Bell; R Barfoot; T Iveson; R L Powles; B C Millar
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

9.  FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway.

Authors:  Cheng-Cao Sun; Wei Zhu; Shu-Jun Li; Wei Hu; Jian Zhang; Yue Zhuo; Han Zhang; Juan Wang; Yu Zhang; Shao-Xin Huang; Qi-Qiang He; De-Jia Li
Journal:  Genome Med       Date:  2020-09-02       Impact factor: 11.117
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.